Ipsen S.A. (OTCMKTS:IPSEY – Get Rating) was the recipient of a significant decline in short interest during the month of April. As of April 30th, there was short interest totalling 600 shares, a decline of 78.6% from the April 15th total of 2,800 shares. Based on an average daily volume of 6,400 shares, the short-interest ratio is currently 0.1 days.
Several equities analysts have commented on the stock. Credit Suisse Group upped their price objective on shares of Ipsen from €87.00 ($91.58) to €105.00 ($110.53) and gave the company a “neutral” rating in a report on Friday, March 25th. Societe Generale upped their price objective on shares of Ipsen from €112.00 ($117.89) to €120.00 ($126.32) and gave the company a “buy” rating in a report on Friday, April 29th. Barclays upped their price objective on shares of Ipsen from €88.00 ($92.63) to €95.00 ($100.00) and gave the company an “underweight” rating in a report on Thursday, April 14th. Bryan, Garnier & Co downgraded shares of Ipsen from a “buy” rating to a “neutral” rating in a research note on Wednesday, April 27th. Finally, AlphaValue upgraded shares of Ipsen to a “reduce” rating in a research note on Thursday, February 17th. Three analysts have rated the stock with a sell rating, six have issued a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.com, Ipsen presently has an average rating of “Hold” and an average price target of $87.25.
IPSEY opened at $23.61 on Friday. Ipsen has a twelve month low of $21.71 and a twelve month high of $32.51. The company has a 50-day simple moving average of $28.81 and a 200 day simple moving average of $26.56.
Ipsen SA operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for metastatic prostate cancer, uterine fibroids, precocious puberty, endometriosis, female sterility, and early stage breast cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, and chronic renal failure, as well as GH deficiency in adults; and Increlex for growth failure in children and adolescents.
- Get a free copy of the StockNews.com research report on Ipsen (IPSEY)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for Ipsen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ipsen and related companies with MarketBeat.com's FREE daily email newsletter.